<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825834</url>
  </required_header>
  <id_info>
    <org_study_id>DELFI-L101 Study</org_study_id>
    <nct_id>NCT04825834</nct_id>
  </id_info>
  <brief_title>DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)</brief_title>
  <acronym>DELFI-L101</acronym>
  <official_title>DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Delfi Diagnostics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Delfi Diagnostics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study, DELFI-L101, is to train and test classifiers for lung&#xD;
      cancer detection using the DELFI assay and other biomarker and clinical features.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be enrolled into the DELFI-L101 study after informed consent and eligibility is&#xD;
      confirmed. At enrollment, subjects will have blood specimens collected (~40 mL) and 12 months&#xD;
      post-enrollment their medical records will be reviewed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of lung cancer detection measured by sensitivity, specificity, and the AUC of the ROC.</measure>
    <time_frame>Approximately 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy (sensitivity and specificity) in clinical subgroups of interest</measure>
    <time_frame>Approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of tumor of origin (confusion matrix of predicted versus actual cancer type)</measure>
    <time_frame>Approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) associated with the blood specimen collection</measure>
    <time_frame>Point in time of blood specimen collection (1day) at enrollment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expected distribution of the DELFI score in the intended use population</measure>
    <time_frame>Approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analytical performance (e.g. repeatability/reproducibility)</measure>
    <time_frame>Approximately 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Stomach Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Individuals eligible for Lung Cancer screening with Lung Cancer diagnosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Individuals eligible for Lung Cancer screening with no cancer diagnosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Individuals eligible for Lung Cancer screening with Non-Lung Cancer diagnosis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Sample Collection</intervention_name>
    <description>Subjects enrolled in the DELFI-L101 will have blood specimens collected (~40 mL) at enrollment.</description>
    <arm_group_label>Individuals eligible for Lung Cancer screening with Lung Cancer diagnosis</arm_group_label>
    <arm_group_label>Individuals eligible for Lung Cancer screening with Non-Lung Cancer diagnosis</arm_group_label>
    <arm_group_label>Individuals eligible for Lung Cancer screening with no cancer diagnosis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Residual blood specimens may be used to develop and evaluate performance of biomarker assays&#xD;
      to detect cancers or other conditions, laboratory process improvements, and proficiency&#xD;
      testing. Residual blood specimens will be de-identified and will be stored for no more than&#xD;
      20 years.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals ≥ 50 years of age who are eligible for lung cancer screening from medical,&#xD;
        surgical, sub- specialty clinics, lung cancer screening, lung nodule, thoracic surgery, and&#xD;
        chest clinic practices.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Subjects:&#xD;
&#xD;
          1. Ability to understand and provide written informed consent&#xD;
&#xD;
          2. Age ≥ 50 years&#xD;
&#xD;
          3. Current or Former Smoker&#xD;
&#xD;
          4. ≥ 20 pack-years (pack years = number of packs per day X number of years smoked)&#xD;
&#xD;
             AND&#xD;
&#xD;
             Inclusion Group 1: High Risk Patients that meet criteria 5 and 6 below:&#xD;
&#xD;
          5. Prior thoracic imaging (computed tomography (CT)) within 12 months of enrollment OR&#xD;
             Planned thoracic imaging (CT) as part of standard of care within 6 weeks of enrollment&#xD;
&#xD;
             AND&#xD;
&#xD;
          6. Meet one of the criteria below:&#xD;
&#xD;
               1. No suspected or confirmed lung cancer diagnosis OR&#xD;
&#xD;
               2. Suspected of lung cancer OR&#xD;
&#xD;
               3. Confirmed, untreated lung cancer&#xD;
&#xD;
             Inclusion Group 2: High Risk Patients with cancer other than lung cancer that meet the&#xD;
             following criteria:&#xD;
&#xD;
          7. Pathologic confirmed, solid-tumor cancer diagnosis, that is not lung cancer or&#xD;
             non-melanoma skin cancer, with no prior systemic therapy, definitive therapy,&#xD;
             radiation, or surgical resection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Subjects:&#xD;
&#xD;
          1. History of previous cancer or therapy for cancer within the year prior to enrollment&#xD;
&#xD;
          2. Any history of hematologic malignancies or myelodysplasia&#xD;
&#xD;
          3. Any history of organ tissue transplantation&#xD;
&#xD;
          4. Any history of blood product transfusion&#xD;
&#xD;
          5. Current pregnancy&#xD;
&#xD;
          6. Any condition that in the opinion of the Investigator should preclude the subject's&#xD;
             participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Peter Mazzone, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shanna Allen</last_name>
    <phone>682-800-2025</phone>
    <email>allen@delfidiagnostics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Mazzone, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Individual participant data that underline the results reported in publications of the study may be shared after de-identification. This may include text, tables, figures, and appendices. The study protocol, statistical analysis plan, and informed consent form will also be shared. Data may be shared with researchers who provide a methodologically sound proposal to achieve the aims outlined in the approved proposal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

